Metabolic and Additional Vascular Effects of Thiazolidinediones

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003495-200262100-00004PMID 12093315
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Troglitazone

  2012cited by this paper
• Effects of Pioglitazone and Metformin on the Development of Hypertension and on Insulin Sensitivity in 1 K 1 C Rats

  2005cited by this paper
• A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.

  2002cited by this paper
• CD36 deficiency associated with insulin resistance

  2002cited by this paper
• Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.

  2002cited by this paper
• Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

  2002cited by this paper
• The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance.

  2001cited by this paper
• Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice: Pleiotropic Effects on CD36 Expression and HDL

  2001cited by this paper
• Down regulation of peroxisome proliferator-activated receptor γ expression by inflammatory cytokines and its reversal by thiazolidinediones

  2001cited by this paper
• Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes.

  2001cited by this paper
• Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice.

  2001cited by this paper
• High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.

  2001cited by this paper
• Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.

  2001cited by this paper
• The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

  2001cited by this paper
• PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.

  2001cited by this paper
• PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

  2001cited by this paper
• Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.

  2001cited by this paper
• Dietary modulation of endothelial function: implications for cardiovascular disease.

  2001cited by this paper
• Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus.

  2001cited by this paper
• Rosiglitazone

  2001cited by this paper
• Pioglitazone Ameliorates Tumor Necrosis Factor-α–Induced Insulin Resistance by a Mechanism Independent of Adipogenic Activity of Peroxisome Proliferator–Activated Receptor-γ

  2001cited by this paper
• Peroxisome Proliferator-Activated Receptors (PPARs) and Their Role in the Vessel Wall: Possible Mediators of Cardiovascular Risk?

  2001cited by this paper
• PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

  2001cited by this paper
• Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.

  2001cited by this paper
• PPARalpha activators inhibit tissue factor expression and activity in human monocytes.

  2001cited by this paper
• The role of PPAR-gamma in macrophage differentiation and cholesterol uptake.

  2001influential reference
• Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors α- and γ-mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus

  2001cited by this paper
• The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance*

  2001cited by this paper
• CD36, insulin resistance, and coronary heart disease.

  2001cited by this paper
• PPARα Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages

  2001cited by this paper
• The role of PPAR-γ in macrophage differentiation and cholesterol uptake

  2001cited by this paper
• CD36 deficiency associated with insulin resistance.

  2001cited by this paper
• Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis.

  2001cited by this paper
• The hormone resistin links obesity to diabetes

  2001cited by this paper
• PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

  2001cited by this paper
• Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects

  2001cited by this paper
• Thiazolidinediones but Not Metformin Directly Inhibit the Steroidogenic Enzymes P450c17 and 3β-Hydroxysteroid Dehydrogenase*

  2001cited by this paper
• A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

  2001cited by this paper
• Peroxisome proliferator-activated receptors in macrophage biology: friend or foe?

  2001cited by this paper
• Peroxisome proliferator-activated receptors in endothelial cell biology

  2001cited by this paper
• Triglycerides, fatty acids and insulin resistance--hyperinsulinemia.

  2001cited by this paper
• A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes.

  2001cited by this paper
• PPARα Activators Inhibit Tissue Factor Expression and Activity in Human Monocytes

  2001cited by this paper
• New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.

  2001cited by this paper
• Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs.

  2001cited by this paper
• Peroxisome Proliferator-activated Receptors in Atherosclerosis and Inflammation—An Update

  2001cited by this paper
• A new look at the heart in diabetes mellitus: from ailing to failing

  2000cited by this paper
• Peroxisome Proliferator–Activated Receptor Activators Inhibit Lipopolysaccharide-Induced Tumor Necrosis Factor-α Expression in Neonatal Rat Cardiac Myocytes

  2000cited by this paper
• Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat.

  2000cited by this paper
• High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells.

  2000cited by this paper
• Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

  2000cited by this paper
• IGF-I inhibits apoptosis induced by serum withdrawal, but potentiates TNF-alpha-induced apoptosis, in 3T3-L1 preadipocytes.

  2000cited by this paper
• Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice.

  2000cited by this paper
• Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells.

  2000cited by this paper
• The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis

  2000cited by this paper
• Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients With Coronary Artery Disease

  2000cited by this paper
• Troglitazone Reduces Reactive Oxygen Species Generation by Leukocytes and Lipid Peroxidation and Improves Flow-Mediated Vasodilatation in Obese Subjects

  2000cited by this paper
• Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.

  2000cited by this paper
• Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action

  2000cited by this paper
• Changing concepts of atherogenesis

  2000cited by this paper
• The perils of portliness: causes and consequences of visceral adiposity.

  2000cited by this paper
• Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo.

  2000cited by this paper
• Role of glucose and insulin in thiazolidinedione-induced alterations in hepatic gluconeogenesis.

  2000cited by this paper
• Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation

  2000cited by this paper
• Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus

  2000cited by this paper
• Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice

  2000cited by this paper
• Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency.

  2000cited by this paper
• Effects of tumor necrosis factor-alpha on basal and stimulated endothelium-dependent vasomotion in human resistance vessel.

  2000cited by this paper
• Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

  2000cited by this paper
• PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.

  2000cited by this paper
• Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report

  2000cited by this paper
• Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.

  2000cited by this paper
• In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.

  2000cited by this paper
• Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.

  2000cited by this paper
• C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives.

  2000cited by this paper
• Activation of Peroxisome Proliferator-Activated Receptor γ Does Not Inhibit IL-6 or TNF-α Responses of Macrophages to Lipopolysaccharide In Vitro or In Vivo

  2000cited by this paper
• Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

  2000cited by this paper
• Hepatic Failure in a Patient Taking Rosiglitazone

  2000cited by this paper
• Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors.

  2000cited by this paper
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

  2000cited by this paper
• The PPARs: from orphan receptors to drug discovery.

  2000cited by this paper
• Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

  2000cited by this paper
• Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency

  2000cited by this paper
• Efficacy of troglitazone on body fat distribution in type 2 diabetes.

  2000cited by this paper
• Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy.

  1999cited by this paper
• Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus.

  1999cited by this paper
• Inhibition of tumor necrosis factor-alpha with anti-diabetic agents.

  1999cited by this paper
• Effects of troglitazone on substrate storage and utilization in insulin-resistant rats.

  1999cited by this paper
• Troglitazone

  1999cited by this paper
• PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells.

  1999cited by this paper
• Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats

  1999cited by this paper
• Medical significance of peroxisome proliferator-activated receptors.

  1999cited by this paper
• Vascular reactivity.

  1999cited by this paper
• Immunomodulators in human seminal plasma: a vital protection for spermatozoa in the presence of infection?

  1999cited by this paper
• Acute troglitazone action in isolated perfused rat liver

  1999cited by this paper
• Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.

  1999cited by this paper
• Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

  1999cited by this paper
• Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes.

  1999cited by this paper
• Effect of troglitazone on body fat distribution in type 2 diabetic patients.

  1999cited by this paper
• Down regulation of peroxisome proliferator-activated receptorγ expression by inflammatory cytokines and its reversal by thiazolidinediones

  1999cited by this paper

• Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals

  2024influential citation
• Food-Based PPARγ Ligands

  2023cites this paper
• Effect of teneligliptin 20 mg twice daily on glucagon like-peptide-1 (GLP-1) levels and its in�uence on non-glycemic components in non-diabetic obese individuals

  2023cites this paper
• The role of peroxisome proliferator‐activated receptor γ in lipid metabolism and inflammation in atherosclerosis

  2023cites this paper
• PPARγ in Atherosclerotic Endothelial Dysfunction: Regulatory Compounds and PTMs

  2023cites this paper
• Evaluation of greenness and whiteness assessment of chemometric assisted techniques for simultaneous determination of canagliflozin, sitagliptin, metformin, pioglitazone, and glimepiride in a quinary mixture

  2023cites this paper
• Molecular docking analysis of PPARγ with phytochemicals from Moroccan medicinal plants

  2023cites this paper
• Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming

  2023cites this paper
• Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin

  2023cites this paper
• Thiazolidinedione as a Promising Medicinal Scaffold for the Treatment of Type 2 Diabetes.

  2023cites this paper
• Action mechanism of hypoglycemic principle 9-(R)-HODE isolated from cortex lycii based on a metabolomics approach

  2022cites this paper
• The Role of Peroxisome Proliferator-Activated Receptor Gamma and Atherosclerosis: Post-translational Modification and Selective Modulators

  2022cites this paper
• Comparative study to evaluate safety and efficacy of Metformin versus sitagliptin alone and combination in type 2 diabetes mellitus

  2022cites this paper
• Comparative study to evaluate the efficacy and safety of Pioglitazone and Metformin on HOMA IR and HbA1c in patient of prediabetes

  2022cites this paper
• The preventive effect of low-dose aspirin in a PPAR-γ antagonist treated mouse model of preeclampsia

  2022cites this paper
• Gene ontology enrichment analysis of PPAR-γ modulators from Cassia glauca in diabetes mellitus

  2021cites this paper
• Atypical antipsychotics and CD36 pathway.

  2021cites this paper
• The preventive function of low-dose aspirin in mice with preeclampsia induced by PPAR-γ antagonist

  2021cites this paper
• Cardiac Protective Effect of Terminalia muelleri Extract in Rat Model of Diabetes Mellitus

  2021cites this paper
• Viburnum opulus L. Juice Phenolics Inhibit Mouse 3T3-L1 Cells Adipogenesis and Pancreatic Lipase Activity

  2020cites this paper
• Coronary Microvascular Dysfunction in Diabetes – Clinical and Research

  2020cites this paper
• Co-administration with Obestatin Reduces Accumulation of Subcutaneous Fat Due to Rosiglitazone Administration in DIO-C57BL/6 Mice

  2020cites this paper
• Co-administration with Obestatin Reduces Accumulation of Subcutaneous Fat Due to Rosiglitazone Administration in DIO-C57BL/6 Mice

  2020cites this paper
• Ciglitazone—a human PPARγ agonist—disrupts dorsoventral patterning in zebrafish

  2019cites this paper
• Therapeutic medications against diabetes: What we have and what we expect.

  2019cites this paper
• Neuroprotective effects of MHY908, a PPAR α/γ dual agonist, in a MPTP-induced Parkinson's disease model.

  2019cites this paper
• Potential role of Peroxisome Proliferator Activated Receptor gamma analogues in regulation of endothelial progenitor cells in diabetes mellitus: An overview.

  2019cites this paper
• Apoptotic cell death in heart failure associated with diabetes

  2019cites this paper
• Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra.

  2019cites this paper
• Selected Phyto and Marine Bioactive Compounds: Alternatives for the Treatment of Type 2 Diabetes

  2018cites this paper
• Targeting Insulin for Alzheimer’s Disease: Mechanisms, Status and Potential Directions

  2018cites this paper
• Design, synthesis, molecular docking, and in vitro antidiabetic activity of novel PPARγ agonist

  2018cites this paper
• PPARγ Alleviates Right Ventricular Failure Secondary to Pulmonary Arterial Hypertension in Rats.

  2017cites this paper
• Preparation and application of a new biochromatography based on small origami assembled PPARγ

  2017cites this paper
• Technology Open Access book

  2017cites this paper
• Prunus mume leaf extract lowers blood glucose level in diabetic mice

  2016cites this paper
• Peroxisome Proliferator‐Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies

  2016cites this paper
• Effects of a PPAR -gamma receptor agonist and an angiotensin receptor antagonist on aortic contractile responses to alpha receptor agonists in diabetic and/or hypertensive rats

  2016cites this paper
• DESIGN, IN-SILICO DOCKING AND PREDICTIVE ADME PROPERTIES OF SOME THIAZOLIDINE-2, 4-DIONES DERIVATIVES AS PPARγ MODULATORS

  2016cites this paper
• Nutrigenomic Approaches to Understanding the Transcriptional and Metabolic Responses of Phytochemicals to Diet‐Induced Obesity and its Complications

  2015cites this paper
• Corrigendum: Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis

  2015cites this paper
• Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome

  2015cites this paper
• Activation of peroxisome proliferator-activated receptor γ ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.

  2015cites this paper
• Development and optimization of novel controlled-release pioglitazone provesicular powders using 32 factorial design

  2015cites this paper
• Vascular endothelial growth factor B-role in metabolism, lipotoxicity and disease

  2015cites this paper
• Prevention of type 2 diabetes

  2015cites this paper
• NONCLINICAL SAFETY EVALUATION OF A NOVEL HYPOGLYCEMIC AGENT PPAR-4; PARTIAL PPAR-γ AGONIST

  2015cites this paper
• Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis

  2015cites this paper
• Oral anti-diabetic agents-review and updates.

  2015cites this paper
• Antiallergic Function of KR62980, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in a Mouse Allergic Rhinitis Model

  2015cites this paper
• Part of the Special Issue: Metabolism 2014 - Alterations of metabolic pathways as therapeutic targets Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARg): a review

  2014cites this paper
• Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.

  2014cites this paper
• ROLE OF PIOGLITAZONE ON PROGRESSION OF ATHEROSCLEROSIS IN PREDIABETES: A MINI REVIEW

  2014cites this paper
• Physicians’ Appraisal and Response to Early Evidence on Cardiovascular Risk Associated with Rosiglitazone: Knowledge Translation in Clinical Practice

  2014cites this paper
• Rosiglitazone modulates pigeon atherosclerotic lipid accumulation and gene expression in vitro.

  2014cites this paper
• Discovery of biaryl-4-carbonitriles as antihyperglycemic agents that may act through AMPK-p38 MAPK pathway.

  2014cites this paper
• Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review

  2014cites this paper
• Effects of pioglitazone on blood glucose and inflammatory markers of diabetic kidney transplant patients: a randomized controlled trial.

  2014cites this paper
• Oxidative Stress, Vascular Remodeling, and Vascular Inflammation in Hypertension

  2013cites this paper
• Fucosylated chondroitin sulfate from Acaudina molpadioides improves hyperglycemia via activation of PKB/GLUT4 signaling in skeletal muscle of insulin resistant mice.

  2013cites this paper
• Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial

  2013cites this paper
• The vascular endothelium in diabetes—a therapeutic target?

  2013cites this paper
• Hypertension in Metabolic Syndrome: Vascular Pathophysiology

  2013cites this paper
• Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.

  2013cites this paper
• Fucosylated Chondroitin Sulfate from Sea Cucumber in Combination with Rosiglitazone Improved Glucose Metabolism in the Liver of the Insulin-Resistant Mice

  2013cites this paper
• Glycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis

  2013cites this paper
• Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity

  2013cites this paper
• Efficacy of Pioglitazone as a Monotherapy on Glycemic Control, Lipids and Blood Pressure in Patients with Type 2 Diabetes Mellitus

  2013cites this paper
• PPAR‐γ – a possible drug target for complicated pregnancies

  2013cites this paper
• Network‐Based Approaches in Drug Discovery and Early Development

  2013cites this paper
• PPARγ activation blocks development and reduces established neuropathic pain in rats.

  2013cites this paper
• Examining the safety of PPAR agonists – current trends and future prospects

  2013cites this paper
• Acute Rosiglitazone Treatment during Reperfusion after Hyperglycemic Stroke is Neuroprotective Not Vascular Protective

  2012cites this paper
• New Drugs for Type 2 Diabetes Mellitus

  2012influential citation
• PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty

  2012cites this paper
• Mechanisms of epithelial cell cancer generation: genetic risk factors on cancer progression investigated using in vivo models and at a single cell level

  2012cites this paper
• Oral Antidiabetic Agents

  2012cites this paper
• Medical Lipid-Regulating Therapy

  2012cites this paper
• Twelve Weeks of Pioglitazone Therapy Significantly Attenuates Dysmetabolism and Reduces Inflammation in Continuous Ambulatory Peritoneal Dialysis Patients—a Randomized Crossover Trial

  2012cites this paper
• The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus

  2012cites this paper
• Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases PPAR- as a therapeutic target in cardiovascular disease: evidence and uncertainty

  2012cites this paper
• Pharmacological modulation of microparticle release: new strategies for the management of atherothrombotic vascular disorders.

  2012cites this paper
• Lipaemia, Inflammation and Atherosclerosis: Novel Opportunities in the Understanding and Treatment of Atherosclerosis

  2012influential citation
• Diabetes and Coronary Heart Disease

  2012cites this paper
• Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus

  2012cites this paper
• 22 PPAR Agonism as New Pharmacological Approach to the Management of Acute Ischemic Stroke

  2012cites this paper
• PPAR Agonism as New Pharmacological Approach to the Management of Acute Ischemic Stroke

  2012cites this paper
• Rosiglitazone reverses increased duodenal inhibitory response in spontaneously hypertensive rats

  2012cites this paper
• Rosiglitazone Causes Endothelial Dysfunction in Humans

  2012cites this paper
• Diabetes Medication Use and Blood Lactate Level among Participants with Type 2 Diabetes: The Atherosclerosis Risk in Communities Carotid MRI Study

  2012influential citation
• Role of Peroxisome Proliferator Activated Receptor-gamma and its Ligands in Inflammatory Bowel Disease

  2012cites this paper
• Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus

  2011cites this paper
• Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs

  2011cites this paper
• The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications.

  2011cites this paper
• Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.

  2011cites this paper
• Curcumin Prevents Experimental Diabetic Retinopathy in Rats Through Its Hypoglycemic, Antioxidant, and Anti-Inflammatory Mechanisms

  2011cites this paper
• Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52‐week, randomized, double‐blind, active‐controlled, parallel‐group study

  2011cites this paper
• Intra-class Differences with Thiazolidinediones: A Clinical Update on the Safety of Treatment for Patients with Type 2 Diabetes

  2011cites this paper
• Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes

  2011cites this paper
• Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.

  2011cites this paper